ELIGIBLE MEDICATIONS

ViiVConnect offers savings and assistance programs for eligible medications*

See below for an overview of eligible medications

APRETUDE

(cabotegravir)

Extended-release injectable suspension: cabotegravir 200 mg/mL

Prescribing Information, including Boxed Warning

Patient Information

Eligible patients may also receive assistance with out-of-pocket costs associated with administration. For additional information, please read the full Eligibility Requirements and Restrictions.

Eligible patients may also receive assistance with out-of-pocket costs associated with administration. For additional information, please read the full Eligibility Requirements and Restrictions.

For more information, visit viivpap.org.

CABENUVA

(cabotegravir; rilpivirine)

Extended-release injectable suspensions: cabotegravir 200 mg/mL; rilpivirine 300 mg/mL

Prescribing Information

Patient Information

Eligible patients may also receive assistance with out-of-pocket costs associated with administration. For additional information, please read the full Eligibility Requirements and Restrictions.

Eligible patients may also receive assistance with out-of-pocket costs associated with administration. For additional information, please read the full Eligibility Requirements and Restrictions.

For more information, visit viivpap.org.

DOVATO

(dolutegravir and lamivudine)

Tablets: 50 mg dolutegravir and 300 mg lamivudine

Blister Pack: 50 mg dolutegravir and 300 mg lamivudine

Prescribing Information, including Boxed Warning

Patient Information

For additional information, please read the full Eligibility Requirements and Restrictions.

For additional information, please read the full Eligibility Requirements and Restrictions.

For more information, visit viivpap.org.

EPIVIR

(lamivudine)

Tablets: 150 mg

Tablets: 300 mg

Oral Solution: 10 mg/mL

Prescribing Information, including Boxed Warning

Patient Information

For more information, visit viivpap.org.

JULUCA

(dolutegravir and rilpivirine)

Tablets: 50 mg dolutegravir and 25 mg rilpivirine

Prescribing Information, including Boxed Warning

Patient Information

For additional information, please read the full Eligibility Requirements and Restrictions.

For additional information, please read the full Eligibility Requirements and Restrictions.

For more information, visit viivpap.org.

RETROVIR

(zidovudine)

Capsules: 100 mg

Prescribing Information, including Boxed Warning

For more information, visit viivpap.org.

RUKOBIA

(fostemsavir)

Extended-Release Tablets: 600 mg

Prescribing Information

Patient Information

For additional information, please read the full Eligibility Requirements and Restrictions.

For additional information, please read the full Eligibility Requirements and Restrictions.

For more information, visit viivpap.org.

SELZENTRY

(maraviroc)

Tablets: 150 mg

Tablets: 300 mg

Prescribing Information, including Boxed Warning

Medication Guide

For more information, visit viivpap.org.

TIVICAY

(dolutegravir)

Prescribing Information

Patient Information

Tablets: 50 mg

For additional information, please read the full Eligibility Requirements and Restrictions.

Tablets: 10 mg

Tablets: 25 mg

Tablets: 50 mg

For additional information, please read the full Eligibility Requirements and Restrictions.

Tablets: 50 mg

For more information, visit viivpap.org.

TIVICAY PD

(dolutegravir)

Tablets for Oral Suspension: 5 mg

Prescribing Information

Patient Information

For additional information, please read the full Eligibility Requirements and Restrictions.

For additional information, please read the full Eligibility Requirements and Restrictions.

For more information, visit viivpap.org.

TRIUMEQ

(abacavir, dolutegravir, and lamivudine)

Tablets: 600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine

Prescribing Information, including Boxed Warning

Medication Guide

For additional information, please read the full Eligibility Requirements and Restrictions.

For additional information, please read the full Eligibility Requirements and Restrictions.

For more information, visit viivpap.org.

TRIUMEQ PD

(abacavir, dolutegravir, and lamivudine)

Tablets for Oral Suspension: 60 mg abacavir, 5 mg dolutegravir, and 30 mg lamivudine

Prescribing Information, including Boxed Warning

Medication Guide

For additional information, please read the full Eligibility Requirements and Restrictions.

For additional information, please read the full Eligibility Requirements and Restrictions.

For more information, visit viivpap.org.

*All savings and assistance programs referenced on this site are subject to eligibility and program requirements and restrictions. These programs do not constitute health insurance. For more information, contact 1-844-588-3288.

†The ViiV Healthcare Patient Assistance Program is operated by the GSK Patient Access Programs Foundation, an independent, non-profit organization separate from ViiV Healthcare.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to ViiV at https://gsk.public.reportum.com or 1-877-844-8872.

PMUS-HVXWCNT260001